SARMs
LGD-4033 (Ligandrol)
LGD-4033 (Ligandrol) is one of the most-studied SARMs, commonly discussed in bulking and lean-mass research. Below, we compare vendors currently stocking research-grade LGD-4033 — not just a single sales page.
LGD-4033 (Ligandrol) is one of the most-studied SARMs, commonly discussed in bulking and lean-mass research. Below, we compare vendors currently stocking research-grade LGD-4033 — not just a single sales page.
Prices and testing claims are pulled from each vendor's product listing. Always confirm current price and COA (Certificate of Analysis) on the vendor's site before buying.
| Vendor | Price | Purity Testing | Code | |
|---|---|---|---|---|
 MuscleChemBest Value |
£49.99 | In-house testing | Buy Here → | |
 UK Sarms |
£54.97 | Third-party COA | Auto-applied | Buy Here → |
 Chemyo |
$79.99 (10mg/ml solution) | Third-party COA | Buy Here → |
LGD-4033 (Ligandrol) is a nonsteroidal selective androgen receptor modulator (SARM) originally developed by Ligand Pharmaceuticals, studied for its potent anabolic activity and comparatively long half-life relative to other SARMs.
Research-grade LGD-4033 is typically supplied as capsules or a liquid solution, commonly at 5mg or 10mg per capsule, intended for laboratory research use only.
LGD-4033 binds the androgen receptor with high affinity and is studied for tissue-selective anabolic activity in muscle, with research interest driven partly by its longer half-life compared to other SARMs, which researchers have noted may support more stable receptor occupancy.
A published Phase 1 human clinical trial found that LGD-4033 increased lean body mass in healthy men over a short treatment period, one of the relatively few SARMs with placebo-controlled human dosing data of this kind.
The same trial documented dose-dependent suppression of markers including SHBG, triglycerides, and free testosterone, findings that are frequently referenced in research discussions of SARM-related HPTA suppression and the rationale for post-cycle-therapy research.
The published Phase 1 trial reported LGD-4033 was generally well tolerated over the short study period, but also documented reversible suppression of testosterone and lipid changes; it has not progressed through Phase 3 trials or received FDA approval, and it is banned by the World Anti-Doping Agency.
Doses used in the published Phase 1 human trial are documented in that trial literature and are specific to that regulated study protocol; no FDA-approved commercial dosage exists for LGD-4033 research material.
Compound X does not sell LGD-4033 (Ligandrol) directly. We provide independent research, comparisons and vendor links — see the vendor comparison table above for current US, UK, Canada and Australia options.
LGD-4033 clinical trial data is indexed on PubMed under "LGD-4033 Ligandrol Phase 1 clinical trial" and "selective androgen receptor modulator lean body mass."
New guides, vendor comparisons and compound breakdowns every week.